Hosting the European Medicines Agency brings considerable economic benefits to the host city as the service employs more than 1,000 people, paid by the EU. Athens and Milan are keen to secure a slice of this lucrative pie.
EU leaders should make a patient-oriented decision on the relocation of the European Medicines Agency (EMA) from London and ensure “minimal disruption”, according to the pharmaceutical industry and consumer groups.
EU member states are urged to put on a united front on the issue of relocating the London-based European Medicines Agency (EMA), rather than bicker publicly and give the UK government reason to believe the bloc cannot cooperate properly, diplomats have told EURACTIV.com.
The debate over where to relocate the London-based European Medicines Agency (EMA) after Brexit has divided the other 27 EU member states, despite calls for an urgent decision from the drugs industry and patient groups.
Leaders of 27 EU member states - excluding the UK -agreed late on Thursday (22 June) on criteria to decide by November the new seats of the European Medicines Agency and the European Banking Authority, which are currently based in London.
Spanish Minister for Health Dolors Montserrat said today (24 May) that Barcelona is “first in the class” in meeting all the criteria to host the European Medicines Agency (EMA). She also insisted that the central government supports Catalonia's bid to host it after Brexit.
The future of EU agencies based in London will be part of tomorrow’s EU-27 summit, an issue that could erode the unity that European leaders want to showcase before the divorce talks with the UK begin.
Pharmaceutical companies called on Thursday (27 April) for a phased transition in drug regulation after Britain leaves the European Union, in order to avoid supply disruption and protect public health.
The future location of the two European Union agencies based in London will be a matter for Brexit negotiations, the British government's Brexit department said yesterday (17 April), but EU officials said there was no doubt they would be moved.
Patient organisations warned the European Council yesterday (12 April) to be “vigilant” in the relocation of the European Medicines Agency (EMA), as well as avoid unnecessary delays that may cause disruptions in healthcare.
Controls on EU immigration played a key role in the Brexit vote. However, the UK government now says that it wants to protect the free movement of researchers and talent, which are crucial for the life sciences sector. EURACTIV.com reports from Lyon.
The criteria regarding the relocation of the European Medicines Agency (EMA) from London after the Brexit vote should not be political, Danish and Greek officials told Euractiv.com on Monday (20 February).
In the aftermath of the Brexit vote, Rome and Madrid are leading the race to gain the right to host influential EU agencies, while Croatia, Bulgaria, Cyprus, Romania and Slovakia could remain empty-handed.
The UK's pharmaceutical regulator would lose influence over the European Medicines Agency (EMA) if Britons vote to leave the EU in a June referendum. As a result, it could well consider aligning itself with its US equivalent, sector advisors have told EURACTIV.com.
Denmark's pharmaceutical industry is going head-to-head with its Swedish counterpart by arguing Denmark should be the new home of the European Medicines Agency (EMA) if Britons vote to leave the European Union in a June referendum.
The need for fast, accurate and balanced information is always important. We value EURACTIV's good, independent journalism and support this initiative
Mella Frewen, Director General of FoodDrinkEurope
EURACTIV plays a vital role in bringing Europe closer to its citizens. EURACTIV has long recognised that the story of Europe has to be told across the continent, and not just in Brussels. We need to support a truly European and informed debate.